Literature DB >> 10428828

Hexokinase II-deficient mice. Prenatal death of homozygotes without disturbances in glucose tolerance in heterozygotes.

S Heikkinen1, M Pietilä, M Halmekytö, S Suppola, E Pirinen, S S Deeb, J Jänne, M Laakso.   

Abstract

Type 2 diabetes is characterized by decreased rates of insulin-stimulated glucose uptake and utilization, reduced hexokinase II mRNA and enzyme production, and low basal levels of glucose 6-phosphate in insulin-sensitive skeletal muscle and adipose tissues. Hexokinase II is primarily expressed in muscle and adipose tissues where it catalyzes the phosphorylation of glucose to glucose 6-phosphate, a possible rate-limiting step for glucose disposal. To investigate the role of hexokinase II in insulin action and in glucose homeostasis as well as in mouse development, we generated a hexokinase II knock-out mouse. Mice homozygous for hexokinase II deficiency (HKII(-/-)) died at approximately 7.5 days post-fertilization, indicating that hexokinase II is vital for mouse embryogenesis after implantation and before organogenesis. HKII(+/-) mice were viable, fertile, and grew normally. Surprisingly, even though HKII(+/-) mice had significantly reduced (by 50%) hexokinase II mRNA and activity levels in skeletal muscle, heart, and adipose tissue, they did not exhibit impaired insulin action or glucose tolerance even when challenged with a high-fat diet.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428828     DOI: 10.1074/jbc.274.32.22517

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Reduction in hexokinase II levels results in decreased cardiac function and altered remodeling after ischemia/reperfusion injury.

Authors:  Rongxue Wu; Kirsten M Smeele; Eugene Wyatt; Yoshihiko Ichikawa; Otto Eerbeek; Lin Sun; Kusum Chawla; Markus W Hollmann; Varun Nagpal; Sami Heikkinen; Markku Laakso; Kentaro Jujo; J Andrew Wasserstrom; Coert J Zuurbier; Hossein Ardehali
Journal:  Circ Res       Date:  2010-11-11       Impact factor: 17.367

Review 2.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Authors:  Nissim Hay
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

3.  Octamer transcription factor-1 induces the Warburg effect via up-regulation of hexokinase 2 in non-small cell lung cancer.

Authors:  Zhen Li; Jin Su; Mingming Sun; Jiaqi Song; Huanran Sun; Jun Fan; Guo Chen; Changliang Shan; Qi Qi; Shuai Zhang
Journal:  Mol Cell Biochem       Date:  2021-05-10       Impact factor: 3.396

4.  The Aspergillus nidulans xprF gene encodes a hexokinase-like protein involved in the regulation of extracellular proteases.

Authors:  M E Katz; A Masoumi; S R Burrows; C G Shirtliff; B F Cheetham
Journal:  Genetics       Date:  2000-12       Impact factor: 4.562

Review 5.  Glucose Metabolism in Cancer.

Authors:  Sminu Bose; Anne Le
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

6.  Quantitative mass spectrometry of diabetic kidney tubules identifies GRAP as a novel regulator of TGF-beta signaling.

Authors:  Timothy D Cummins; Michelle T Barati; Susan C Coventry; Sarah A Salyer; Jon B Klein; David W Powell
Journal:  Biochim Biophys Acta       Date:  2009-10-22

7.  Partial hexokinase II knockout results in acute ischemia-reperfusion damage in skeletal muscle of male, but not female, mice.

Authors:  Kirsten M Smeele; Otto Eerbeek; Anneke Koeman; Rick Bezemer; Can Ince; Sami Heikkinen; Markku Laakso; Arnold de Haan; Gert Schaart; Maarten R Drost; Markus W Hollmann; Coert J Zuurbier
Journal:  Pflugers Arch       Date:  2010-02-25       Impact factor: 3.657

8.  Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice.

Authors:  Vijay K Yechoor; Mary-Elizabeth Patti; Robert Saccone; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

9.  HKDC1 Is a Novel Hexokinase Involved in Whole-Body Glucose Use.

Authors:  Anton E Ludvik; Carolina M Pusec; Medha Priyadarshini; Anthony R Angueira; Cong Guo; Amy Lo; Korri S Hershenhouse; Guang-Yu Yang; Xianzhong Ding; Timothy E Reddy; William L Lowe; Brian T Layden
Journal:  Endocrinology       Date:  2016-07-26       Impact factor: 4.736

10.  Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.

Authors:  Qi Wang; Prashanth T Bhaskar; Krushna C Patra; Luke Miller; Zebin Wang; Will Wheaton; Navdeep Chandel; Markku Laakso; William J Muller; Eric L Allen; Abhishek K Jha; Gromoslaw A Smolen; Michelle F Clasquin; Brooks Robey; Nissim Hay
Journal:  Cancer Cell       Date:  2013-08-01       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.